Olfactory Neuroblastoma: The University of Erlangen‐Nuremberg Experience 1975–2000

Constantinidis, Jannis; Steinhart, Helmut; Koch, Michael; Buchfelder, Michael; Schänzer, Anne; Weidenbecher, M.; Iro, Heinrich

doi:10.1016/j.otohns.2003.10.010

Cited by 91 publications

(66 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Additionally, humans are virtually unable to lateralize olfactory stimuli [6,20,21]. From the clinical point of view, this issue is reflected by a very low percentage of patients with an olfactory neuroblastoma who complain about unilateral olfactory loss [3].…”

Section: Introductionmentioning

confidence: 99%

Unilateral reduced sense of smell is an early indicator for global olfactory loss

Gudziol¹,

Paech²,

Hummel³

2010

J Neurol

View full text Add to dashboard Cite

It is estimated that 15% of normosmic subjects demonstrate lateralized smell loss. The majority of individuals will not notice this difference between nostrils as long as olfactory function of the better nostril remains in the normal range. We were interested in the question whether subjects demonstrating clinically significant side differences of olfactory function are at risk to develop bilateral olfactory loss. Normosmic individuals with such side differences ("difference group", n = 35) were re-tested on average 4.6 years after baseline investigations. Additionally, 58 subjects who did not demonstrate side differences ("control group") were also re-investigated. All participants received detailed olfactory testing using the "Sniffin' Sticks" involving tests for odor threshold, odor discrimination, and odor identification. Olfactory testing at follow-up indicated lower olfactory function (p = 0.005) in the "difference group" than in the "control group". The degree of side difference at baseline correlated negatively with the results from olfactory testing at follow-up (r = -0.29; p = 0.01). These results suggest that individuals with side differences of olfactory function are at risk to develop bilateral olfactory loss within 4.5 years. Thus, the degree of lateralized smell function is an indicator for future smell loss.

show abstract

Section: Introductionmentioning

confidence: 99%

Unilateral reduced sense of smell is an early indicator for global olfactory loss

Gudziol¹,

Paech²,

Hummel³

2010

J Neurol

View full text Add to dashboard Cite

show abstract

“…Our experience suggested that most patients were sensitive to radiotherapy and could obtain excellent disease control, so irrespective of the staging, all the patients of ENB in our hospital received preoperative radiotherapy after confirmation by preoperative biopsy. On the other hand, some institutions reported that when radiotherapy is given preoperatively, the determination of tumor margins and tissue planes can be complicated and result in an increased risk of incomplete resection [9,10] .…”

Section: Discussionmentioning

confidence: 99%

Diagnosis and Management of Esthesioneuroblastoma

Zhang¹,

Zhou²,

Wang³

et al. 2010

ORL

View full text Add to dashboard Cite

Aims: Our purpose was to evaluate the diagnosis and combined modality treatment of esthesioneuroblastoma treated at 1 institution. Methods: A retrospective analysis of clinical information regarding presentation, immunohistochemical results, treatment and outcome was performed on 21 patients with esthesioneuroblastoma. Results: Two patients had Kadish A, 12 had Kadish B and 7 had Kadish C disease. The mean follow-up was 41.9 months. Immunohistochemical stains were performed in 17 cases, and the tumors were focal positive or showed positive immunoreactivity to neuron-specific enolase (17/17, 100%), synaptophysin (13/17, 76.5%), S-100 protein (8/17, 47.1%), epithelial membrane antigen (5/17, 29.4%), chromogranin A (4/17, 23.5%), vimentin (3/17, 17.6%) and cytokeratin (2/17, 11.8%). Generally, the patients were treated with preoperative radiotherapy (Kadish A and Kadish B) and preoperative chemoradiotherapy (Kadish C) after the initial biopsy, followed by surgery. Surgical approaches (n = 21) consisted of 12 lateral rhinotomies, 5 craniofacial resections, 3 endoscopic sinus surgeries and 1 midfacial degloving approach. The 5-year crude overall survival rate was 76.2%. Conclusions: Esthesioneuroblastoma is an uncommon malignant tumor. Thorough histological evaluation is the key to correct diagnosis and differentiation. Preoperative radiotherapy or chemoradiotherapy can give surgeons the chance to choose different surgical approaches, especially the endoscopic surgical techniques, in the future.

show abstract

“…L'extension de la tumeur peut se faire en direction des sinus, de la lame criblée, et des orbites. Dans ces derniers cas, douleurs, lacrymation, céphalées frontales et proptose s'ajoutent au tableau [12]. L'évolution peut être indolente sur plusieurs années ou au contraire très agressive.…”

Section: Sphère Orl Esthésioneuroblastome (Enb)unclassified

“…L'évolution peut être indolente sur plusieurs années ou au contraire très agressive. Les sites métastatiques les plus fréquents sont les ganglions cervicaux (10 à 30 %) alors que les métastases hématogènes (poumons, cerveau, os) sont moins fréquentes [12,13]. L'examen clinique révèle souvent une masse polypoïde dans la cavité nasale, alors que l'examen anatomopathologique décrit une tumeur formée de petites cellules rondes, avec un noyau hyperchrome, et un stroma bien vascularisé et oedématié.…”

Section: Sphère Orl Esthésioneuroblastome (Enb)unclassified

Les tumeurs rares

Peters

Mirimanoff

2011

Thérapeutique Du Cancer

View full text Add to dashboard Cite

Olfactory Neuroblastoma: The University of Erlangen‐Nuremberg Experience 1975–2000

Cited by 91 publications

References 25 publications

Unilateral reduced sense of smell is an early indicator for global olfactory loss

Unilateral reduced sense of smell is an early indicator for global olfactory loss

Diagnosis and Management of Esthesioneuroblastoma

Les tumeurs rares

Contact Info

Product

Resources

About